Brian Gorman
General Counsel bei CALLIDITAS THERAPEUTICS AB
Profil
Brian Gorman is currently the Group General Counsel at Calliditas Therapeutics AB since 2024.
Prior to this, he worked as the EVP-Corporate Development & General Counsel at Opiant Pharmaceuticals, Inc. and as the Vice President & Assistant General Counsel at Endo Pharmaceuticals, Inc. He completed his undergraduate degree at Gettysburg College and his graduate degree at Villanova University School of Law.
Aktive Positionen von Brian Gorman
Unternehmen | Position | Beginn |
---|---|---|
CALLIDITAS THERAPEUTICS AB | General Counsel | 01.01.2024 |
Ehemalige bekannte Positionen von Brian Gorman
Unternehmen | Position | Ende |
---|---|---|
OPIANT PHARMACEUTICALS, INC. | General Counsel | 02.03.2023 |
Endo Pharmaceuticals, Inc.
Endo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Endo Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products. The company provides research and development of generic pharmaceutical products for controlling pain. Its product includes Lidoderm, Percocet, Percodan, Frova, DepoDur, and Zydone. The company is headquartered in Malvern, PA. | General Counsel | - |
Ausbildung von Brian Gorman
Villanova University School of Law | Graduate Degree |
Gettysburg College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CALLIDITAS THERAPEUTICS AB | Health Technology |
Private Unternehmen | 2 |
---|---|
Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Richmond, VA. | Health Technology |
Endo Pharmaceuticals, Inc.
Endo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Endo Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products. The company provides research and development of generic pharmaceutical products for controlling pain. Its product includes Lidoderm, Percocet, Percodan, Frova, DepoDur, and Zydone. The company is headquartered in Malvern, PA. | Health Technology |